These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22181051)

  • 1. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies.
    Burudpakdee C; Zhao Z; Munakata J; Gao S; Trochlil K; Barber B
    J Med Econ; 2012; 15(2):371-7. PubMed ID: 22181051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of monoclonal antibodies for treatment of colorectal cancer.
    Berger MD; Lenz HJ
    Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
    Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
    J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of hospital events in patients with metastatic colorectal cancer.
    Overbeek JA; Zhao Z; van Herk-Sukel MP; Barber BL; Gao S; Herings RM
    J Med Econ; 2011; 14(5):656-61. PubMed ID: 21854190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
    Saif MW; Longo WL; Israel G
    Clin Colorectal Cancer; 2008 Mar; 7(2):144-8. PubMed ID: 18501075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intricacies of bevacizumab-induced toxicities and their management.
    Gressett SM; Shah SR
    Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012).
    Ward A; Alvarez P; Vo L; Martin S
    J Med Econ; 2014 Mar; 17(3):176-83. PubMed ID: 24410011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.
    Bilir SP; Ma Q; Zhao Z; Wehler E; Munakata J; Barber B
    Am Health Drug Benefits; 2016 Jun; 9(4):203-13. PubMed ID: 27688833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing patients treated with bevacizumab combination therapy.
    Gordon MS; Cunningham D
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of toxicities associated with treating metastatic melanoma in eight countries.
    Wehler E; Zhao Z; Pinar Bilir S; Munakata J; Barber B
    Eur J Health Econ; 2017 Jan; 18(1):49-58. PubMed ID: 26721505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
    Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
    Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimates of charges associated with emergency department and hospital inpatient care for opioid abuse-related events.
    Chandwani HS; Strassels SA; Rascati KL; Lawson KA; Wilson JP
    J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):206-13. PubMed ID: 23879214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.